Deal Watch: Merck Gets Rights To Yumanity’s Preclinical ALS, FTLD Candidates
Executive Summary
Merck pays undisclosed upfront fees and promises up to $500m for milestones under licensing and collaboration agreement. Meanwhile, Tetraphase and Xerava are being acquired by La Jolla, after previous bids by Melinta and AcelRx.
You may also be interested in...
Innoviva Aims For Antibiotic Success With La Jolla, Entasis Acquisitions
Having recently bought antibacterial developer Entasis, Innoviva adds approved antibiotic Xerava and hypotension drug Giapreza to its portfolio along with La Jolla’s established commercial organization.
Yumanity To Reverse Merge With Kineta Two Years After Its Own Public Debut
After its August 2020 reverse merger, neuroscience-focused Yumanity is calling it quits with two transactions: an asset sale to Janssen and a merger with private cancer immunotherapy firm Kineta.
Ocuphire Posts Second Phase III Success In Reversing Pupil Dilation
Nyxol is almost set for an NDA filing for reversal of dilation during eye exams/surgery. The reformulation of phentolamine is also being studied in presbyopia, setting up possible competition with AbbVie’s Vuity.